PMID- 35116548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 10
IP  - 5
DP  - 2021 May
TI  - Decreased expression of nuclear factor 90 correlates with worse outcomes in 
      nasopharyngeal carcinoma.
PG  - 2318-2327
LID - 10.21037/tcr-20-2252 [doi]
AB  - BACKGROUND: Nuclear factor 90 (NF90), one of the double-stranded RNA binding 
      proteins (DSRBP), is involved in many cellular biological processes, includes 
      cell proliferation, differentiation, angiogenesis, cell cycle and immunity. 
      However, its role in nasopharyngeal carcinoma (NPC), and the significance of 
      expression in clinics, remains unknown. The aim of this study was to uncover the 
      relationship between the NF90 expression by immunohistochemistry (IHC) and 
      clinical outcomes in NPC patients. METHODS: We retrospectively detected the NF90 
      expression in 216 NPC specimens by IHC. The cutoff value of NF90 was evaluated 
      using receiver operating characteristic (ROC) curve, the prognostic value of NF90 
      in NPC was evaluated by Kaplan-Meier and cox multifactor statistical model. 
      RESULTS: Elevated expression of NF90 was found in 60.2% (130/216). Positive 
      correlation was found between NF90 expression and clinical stage (P=0.018), T 
      stage (P=0.004), and therapy (P=0.020). Over-expression of NF90 predicted 
      favorable progression-free survival (PFS) (P=0.017) and overall survival (OS) 
      (P<0.001) in NPC. Further analysis suggested that the level of NF90 expression 
      was an independent risk factor in NPC prognosis. CONCLUSIONS: These results 
      demonstrate, for the first time, that decreased expression of NF90 is an 
      independent biomarker of worse prognosis for NPC patients, and is a great 
      potential tool for screening the high-risk population for advanced NPC patients.
CI  - 2021 Translational Cancer Research. All rights reserved.
FAU - Li, Yong
AU  - Li Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma 
      Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Fu, Jianchang
AU  - Fu J
AD  - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Li, Zi-Zi
AU  - Li ZZ
AD  - Department of Pathology, the Fifth Affiliated Hospital of Sun Yat-sen University, 
      Zhuhai, China.
FAU - Zhu, Qiufang
AU  - Zhu Q
AD  - Department of Pathology, Zhuhai People's Hospital, Zhuhai, China.
FAU - Chen, Keming
AU  - Chen K
AD  - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Du, Huixiong
AU  - Du H
AD  - Department of Pathology, Zhuhai People's Hospital, Zhuhai, China.
FAU - Liu, Jun
AU  - Liu J
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma 
      Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Li, Yingqing
AU  - Li Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma 
      Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798305
OTO - NOTNLM
OT  - Nasopharyngeal carcinoma (NPC)
OT  - nuclear factor 90 (NF90)
OT  - prognosis
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-2252). The authors have no 
      conflicts of interest to declare.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/05/01
CRDT- 2022/02/04 05:49
PHST- 2020/06/03 00:00 [received]
PHST- 2021/02/18 00:00 [accepted]
PHST- 2022/02/04 05:49 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/05/01 00:00 [pmc-release]
AID - tcr-10-05-2318 [pii]
AID - 10.21037/tcr-20-2252 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2021 May;10(5):2318-2327. doi: 10.21037/tcr-20-2252.